IL6 and COVID-19: Since the pandemic started, COVID-19 therapy has made remarkable progress, introducing monoclonal anti-IL-6 antibodies such as tocilizumab or anti-IL-1R antibodies such as Anakinra; inhibitors of Janus kinase (JAK) such as baricitinib; and different antivirals including remdesivir, molnupiravir, nirmatrelvir/ritonavir, casirivimab/imdevimab, bamlanivimab/etesevimab, and tixagevimab/cilgavimab [14].